STOCK TITAN

Intellia Therapeutics, Inc - NTLA STOCK NEWS

Welcome to our dedicated page for Intellia Therapeutics news (Ticker: NTLA), a resource for investors and traders seeking the latest updates and insights on Intellia Therapeutics stock.

Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a pioneering clinical-stage gene editing company dedicated to revolutionizing medicine through the use of CRISPR-based therapies. Founded in 2014 by Caribou Biosciences and Atlas Venture, along with leading scientists in the field, Intellia harnesses the potential of CRISPR/Cas9 technology to develop curative treatments for a variety of genetically defined diseases.

The company's core mission is to leverage CRISPR/Cas9—an innovative technology adapted from a natural cellular process that allows for precise and flexible gene editing. This technology enables the correction of specific DNA sequences within any organism, opening new frontiers in biomedical research and clinical interventions.

Intellia's portfolio includes both in vivo and ex vivo gene editing programs. The in vivo programs aim to edit disease-causing genes directly within the human body, targeting conditions such as ATTR amyloidosis, hereditary angioedema (HAE), and alpha-1 antitrypsin deficiency. Notable achievements include the interim results from their NTLA-2002 program for HAE, which showed a 95% reduction in monthly attack rates, with most patients remaining attack-free.

The ex vivo programs focus on engineering human cells outside the body to treat cancer and autoimmune diseases. These programs include collaborations with prominent companies like Regeneron and Novartis, which help advance their therapeutic pipeline.

Intellia's financial condition reflects its robust pipeline and strategic partnerships. The company recently reported strong enrollment progress in their pivotal Phase 3 MAGNITUDE trial for NTLA-2001 targeted at ATTR amyloidosis with cardiomyopathy. They have also formed a strategic collaboration with ReCode Therapeutics to develop treatments for cystic fibrosis, utilizing ReCode's Selective Organ Targeting (SORT) lipid nanoparticle delivery platform.

Committed to advancing the field of gene editing, Intellia continues to expand its CRISPR-based platform with novel editing and delivery technologies. The company remains at the forefront of a new era in medicine, as evidenced by its ongoing clinical trials and promising preliminary data.

For more detailed information and the latest updates, investors and stakeholders are encouraged to visit www.intelliatx.com and follow Intellia on Twitter @intelliatx.

Rhea-AI Summary

Intellia Therapeutics (NASDAQ:NTLA) has received the Innovation Passport from the U.K. Medicines and Healthcare products Regulatory Agency for NTLA-2002, a genome editing therapeutic candidate aimed at treating hereditary angioedema (HAE). This designation allows entry into the Innovative Licensing and Access Pathway (ILAP), facilitating faster market access for innovative medicines. The Phase 2 portion of NTLA-2002's clinical study is expected to start in the first half of 2023, following ongoing Phase 1/2 trials focusing on the drug's safety and effectiveness.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
none
-
Rhea-AI Summary

Intellia Therapeutics (NASDAQ: NTLA) outlines its strategic priorities for 2023-2024, emphasizing late-stage development of CRISPR-based therapies NTLA-2001 and NTLA-2002. Key milestones include submitting IND applications for these treatments and initiating pivotal global studies by the end of 2023. The company ended 2022 with approximately $1.3 billion in cash, indicating a strong financial position. Intellia aims to advance novel gene editing technologies and maintain its leadership in genome editing through high-impact opportunities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
none
-
Rhea-AI Summary

Intellia Therapeutics (NASDAQ:NTLA) has priced a public offering of 6,550,219 shares at $45.80 each, aiming to raise approximately $300 million. The underwriter, Goldman Sachs, has a 30-day option for an additional 982,532 shares. The offering is set to close around December 2, 2022, based on standard conditions. The shares are offered under an existing SEC registration statement. Intellia specializes in CRISPR-based genome editing therapies, focusing on potential cures for diseases through innovative therapeutic approaches.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11%
Tags
Rhea-AI Summary

Intellia Therapeutics (NASDAQ: NTLA) announced a public offering of $250 million in common stock, with a potential additional 15% option for underwriters. Goldman Sachs & Co. LLC is the sole underwriter. The offering is subject to market conditions and follows an effective shelf registration with the SEC. A preliminary prospectus will be available soon. The funds raised are intended to enhance Intellia's development of CRISPR-based therapies. However, there is no guarantee on the offering's completion or terms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11%
Tags
-
Rhea-AI Summary

Intellia Therapeutics has released promising interim data from its Phase 1/2 clinical trial of NTLA-2002, a CRISPR-based therapy for hereditary angioedema (HAE). Results show robust reductions in plasma kallikrein levels and HAE attack rates across all tested doses. Notably, patients in the 25 mg and 75 mg cohorts remain attack-free through the latest follow-up, with intervals lasting between 5.5 to 10.6 months. The treatment was well-tolerated, with no serious adverse effects reported. An investor event discussing these findings is scheduled for November 14, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3%
Tags
none
-
Rhea-AI Summary

Intellia Therapeutics (NASDAQ:NTLA) has presented interim results from its Phase 1 trial of NTLA-2001, a CRISPR-based treatment for ATTR amyloidosis with cardiomyopathy. Results showed a remarkable 90% mean serum TTR reduction following a single dose, sustained for four to six months. NTLA-2001 was generally well-tolerated, with minimal adverse reactions. This study marks a significant step in exploring the potential of NTLA-2001 to permanently inactivate the TTR gene, offering a promising future for patients with this life-threatening condition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.73%
Tags
Rhea-AI Summary

Intellia Therapeutics (NTLA) reported significant interim results from its clinical trials for NTLA-2001 and NTLA-2002 in the third quarter of 2022. NTLA-2001 showed mean serum transthyretin protein reductions of 93% and 92% at doses of 0.7 mg/kg and 1.0 mg/kg, respectively. The firm has strong cash reserves of $848.7 million and expects to initiate Phase 2 of NTLA-2002 by early 2023. Collaboration revenue increased to $13.3 million, while R&D expenses rose to $96.7 million. The net loss was reported at $113.2 million, indicating an increase compared to the previous year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
-
Rhea-AI Summary

Intellia Therapeutics (NASDAQ: NTLA) announced new interim clinical data from its Phase 1/2 study of NTLA-2002, showcasing safety, kallikrein reduction, and attack rate information. This investigational CRISPR/Cas9 therapy aims to prevent angioedema attacks in hereditary angioedema (HAE) patients. Key presentation details include:

  • Date: Nov 12, 2022
  • Presenter: Dr. Hilary Longhurst

A live webcast to discuss the data will be held on Nov 14, 2022. NTLA-2002 represents a novel approach to a rare genetic disorder affecting 1 in 50,000 people.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
conferences clinical trial
-
Rhea-AI Summary

Intellia Therapeutics, Inc. (NASDAQ:NTLA) will present its Q3 2022 financial results and operational highlights on a conference call scheduled for November 3, 2022, at 8 a.m. ET. Investors can participate by dialing 1-833-316-0545 (U.S.) or 1-412-317-5726 (international). A live webcast will also be available on the company’s website. Intellia focuses on developing genome editing therapies through CRISPR technology, aiming to address various diseases with its in vivo and ex vivo programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
Rhea-AI Summary

Intellia Therapeutics (NASDAQ:NTLA) announced upcoming presentations at two investor conferences in October 2022. The Chardan’s 6th Annual Genetic Medicines Conference is scheduled for October 3, 2022, at 8:30 a.m. ET in a fireside chat format. The 2022 Truist Securities Genetic Medicine Summit will include a genome editing panel on October 20, 2022, at 9:00 a.m. ET. A live webcast of the Chardan presentation will be available on Intellia's website, with a replay accessible for 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
conferences

FAQ

What is the current stock price of Intellia Therapeutics (NTLA)?

The current stock price of Intellia Therapeutics (NTLA) is $12.18 as of December 20, 2024.

What is the market cap of Intellia Therapeutics (NTLA)?

The market cap of Intellia Therapeutics (NTLA) is approximately 1.3B.

What is the mission of Intellia Therapeutics?

Intellia Therapeutics aims to develop curative medicines using CRISPR/Cas9 gene editing technology.

What diseases is Intellia targeting with their CRISPR-based therapies?

Intellia targets genetically defined diseases such as ATTR amyloidosis, hereditary angioedema (HAE), sickle cell disease, and cystic fibrosis.

What are Intellia's key advancements in hereditary angioedema (HAE) treatment?

Intellia's NTLA-2002 program for HAE has shown a 95% reduction in monthly attack rates, with most patients remaining attack-free.

When was Intellia Therapeutics founded?

Intellia Therapeutics was founded in 2014.

Who are Intellia's key collaborators?

Intellia has collaborations with Regeneron, Novartis, and ReCode Therapeutics.

What is CRISPR/Cas9?

CRISPR/Cas9 is a gene editing technology that allows for precise modification of DNA sequences, adapted from a natural cellular process.

How does Intellia's in vivo program work?

Intellia's in vivo programs use CRISPR to edit disease-causing genes directly inside the human body.

What are the recent financial highlights of Intellia Therapeutics?

Intellia recently reported strong enrollment progress in their Phase 3 MAGNITUDE trial for NTLA-2001.

What is the scope of Intellia's collaboration with ReCode Therapeutics?

The collaboration aims to develop genomic medicines for cystic fibrosis using Intellia's CRISPR-based platform and ReCode's SORT LNP delivery platform.

Where can I find more information about Intellia Therapeutics?

Visit Intellia's website at www.intelliatx.com and follow them on Twitter @intelliatx.

Intellia Therapeutics, Inc

Nasdaq:NTLA

NTLA Rankings

NTLA Stock Data

1.26B
100.15M
1.21%
91.4%
16.07%
Biotechnology
In Vitro & in Vivo Diagnostic Substances
Link
United States of America
CAMBRIDGE